Browse the evidence

Obesity increases the risk for Type 2 diabetes, hypertension, and cardiovascular disease.

Healthcare providers should prioritize weight management in patients with cardiovascular disease.

Recent guidelines prioritize pharmacologic interventions for weight management in Type 2 diabetes.

Healthcare providers should consider pharmacologic options for weight management in diabetic patients.

The oral formulation of semaglutide reduced AF incidence by 52%.

The oral formulation of semaglutide may be particularly effective in reducing AF risk.

Prandial insulin doses in the treatment of people with diabetes should take into account the pre-meal glycemia as well as the size and composition of meals.

Practitioners should consider both glycemia and meal composition when determining insulin doses.

Semaglutide use is effective in patients with IBD and obesity, resulting in a mean weight loss of over 5%.

Clinicians can consider semaglutide as a viable weight loss option for patients with IBD and obesity.

Semaglutide is associated with weight loss in adults.

Practitioners can consider semaglutide as a treatment option for weight loss in adults with type 2 diabetes or obesity.

Semaglutide improves control of diabetes in adults.

Practitioners can utilize semaglutide to enhance diabetes management in adults.

GLP-1 receptor agonists (GLP-1 RA) are a safe and effective treatment for weight regain and insufficient weight loss after metabolic bariatric surgery.

Practitioners can consider GLP-1 RA as a viable option for patients struggling with weight management post-surgery.

Weekly semaglutide leads to significantly greater weight loss compared to daily liraglutide.

Clinicians may prefer semaglutide over liraglutide for enhanced weight loss outcomes.

Women on hormone therapy (HT) had a higher total body weight loss percentage (TBWL%) at 3, 6, 9, and 12 months compared to women not on HT.

Practitioners may consider hormone therapy as a factor in weight loss strategies for postmenopausal women.

A greater percentage of women on HT achieved ≥5% and ≥10% total body weight loss at 12 months.

This suggests that hormone therapy may enhance the effectiveness of weight loss treatments.

Tirzepatide significantly decreased food intake and reduced overall appetite scores.

Tirzepatide may help reduce appetite, aiding in weight loss efforts.

The use of GLP-1 receptor agonists (GLP-1RAs) post-bariatric treatment results in a weight reduction of 7.83 kg compared to pre-treatment.

GLP-1RAs can be an effective strategy for weight management in patients after bariatric surgery.

In randomized controlled trials, GLP-1RAs induce a weight reduction of 4.36 kg compared to placebo.

GLP-1RAs can be beneficial for weight loss in a controlled setting post-bariatric surgery.

GLP-1 receptor agonists provide an effective alternative to metabolic surgery and dietary interventions for obesity treatment.

GLP-1 receptor agonists may be recommended as a non-surgical option for managing obesity.

There is good evidence for the efficacy and tolerability of approved anti-obesity pharmacotherapies in individuals with T2DM.

Clinicians should consider approved anti-obesity medications as part of treatment for patients with T2DM.

Incretin hormone agonists offer substantial weight reduction and cardiometabolic benefits.

Practitioners can consider incretin hormone agonists as effective options for obesity management.

Weight loss effectively reduces proinflammatory markers and hormones associated with increased risk of endometrioid EC.

Reducing weight can lower the risk factors for endometrial cancer in obese individuals.

Emerging antidiabetic medications show impressive antihyperglycemic effects and remarkable weight loss.

Practitioners should consider these new medications for managing T2D due to their dual benefits.

The dual agonist tirzepatide has shown enhanced potency for weight loss compared to conventional GLP-1 mono agonist.

Practitioners may consider tirzepatide as a more effective option for weight loss in obese patients.

GLP-1 receptor agonists produce significant weight loss.

Practitioners can consider GLP-1 receptor agonists as a viable option for weight loss in patients with obesity.

GLP-1 receptor agonists (GLP-1RAs) have proven efficacy in glucoregulation and weight loss.

Practitioners can consider GLP-1RAs as effective treatment options for managing diabetes and obesity.

Tirzepatide facilitated unprecedented weight loss of up to 22.5% in non-diabetic individuals living with obesity.

This indicates that tirzepatide can be a significant option for weight management in obese individuals.

Tirzepatide provides glycemic lowering and weight loss effects.

Tirzepatide may be effective for patients needing to lower blood sugar and lose weight.